We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Debiopharm Moves Forward Three of its Oncology Clinical Programs
Product News

Debiopharm Moves Forward Three of its Oncology Clinical Programs

Debiopharm Moves Forward Three of its Oncology Clinical Programs
Product News

Debiopharm Moves Forward Three of its Oncology Clinical Programs


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Debiopharm Moves Forward Three of its Oncology Clinical Programs"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Debiopharm Group™ (Debiopharm) has announced that new data on the investigational compounds Debio 1143 (SMAC mimetic), Debio 1347/CH5183284 (FGFR 1,2,3 inhibitor), and Debio 0932 (Hsp90 inhibitor) will be presented at the 50th American Society of Clinical Oncology (ASCO) Annual Meeting, May 30 to June 3, 2014, in Chicago.

Debio 1143 is an orally available small molecule inhibitor of apoptosis proteins (IAPs) that mimicks the activity of the natural second mitochondrial-derived activator of caspases (SMAC). By targeting IAPs, Debio 1143 can induce cancer cell death and potentiate the efficacy of chemo- and/or radiotherapy. Debio 1143 has been assessed in two phase I clinical studies and two phase I/II trials are ongoing in Europe.

Debio 1347/CH5183284 is a selective oral fibroblast growth factor receptor (FGFR) 1, 2, 3 inhibitor that has shown anti-cancer efficacy in several preclinical animal models in vivo. Debio 1347/CH5183284 will enable personalized treatments and will be developed with a companion diagnostic.

Debio 1347/CH5183284 is currently being evaluated in Europe and USA, in a first-in-man phase I trial in patients with advanced solid tumors displaying alterations of the FGFR 1, 2, or 3 genes.

Debio 0932 is a small oral molecule inhibitor of heat shock protein 90 (HSP90). Inhibition of HSP90 results in the degradation of oncoproteins that drive malignant progression and leads to cell death. Debio 0932 has shown efficacy in various mouse tumor xenografts and exhibits sustained tumor retention.

Debio 0932 has been investigated in one phase I clinical study. Two phase I/II studies are ongoing in Europe in advanced non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC) in combination with SOC and everolimus, respectively.

"We are very pleased to present results of our strong involvement in cancer treatment research and further establish our commitment to this challenging medical field" said Jean-Maurice Dumont, Vice President Medical Affairs". "The ability to relieve people with cancer is an accomplishment".

Advertisement